Oral lichen planus associated with candidiasis during secukinumab treatment

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

“…Although it has a favorable safety profile, 2 cases of associated oral lichen planus (OLP)/lichenoid mucositis have been recently described. 1 , 2 …”

Bullous acral eruption related to secukinumab

“…Reported skin related adverse events from phase 3 trials of secukinumab for psoriasis include oral herpes, urticaria, tinea pedis, oral candidiasis, and impetigo, though case reports of other cutaneous reactions have been reported (Table 1), [4,[6][7][8][9][10][11][12][13][14][15][16][17][18]. The Naranjo score is a tool that can help determine the likelihood that a medication in question is responsible for the adverse reaction, which in this case is three (Table 2), [19].…”

“…However, details specific to this patient's course make the score's interpretation imperfect, with a score of three indicating only possible causality. In this case, Truncal pruritic and psoriasiform eruptions [6][7][8] Lichen planus/lichenoid reaction [9][10][11][12] Bullous pemphigoid [13] Subacute cutaneous lupus erythematosus [14] Severe mucositis [15] Granuloma annulare [16] Dermatophytosis [17] Recurrent angular cheilitis [18] Dermatology Online Journal || Case Presentation secukinumab was only made publicly available in 2015 and so reports of reactions are limited. As the patient's reaction was severe and led to hospital admission, rechallenge of the medication was not done, particularly since multiple alternative treatments exist for psoriasis.…”

Cutaneous Lichen Planus Induced by Secukinumab

“…Secukinumab has recently been associated with cutaneous LP, post-development of oral LP during administration of infliximab (tumour necrosis factor-α antagonist) [3]. It has also been linked to induction of oral LP, but never directly to cutaneous LP [4]. Herein, we report the first case of direct druginduced cutaneous LP in the setting of secukinumab for treatment of chronic plaque psoriasis.…”